ST. PAUL, Minn., July 17, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its second quarter fiscal 2025 financial results on Thursday, Aug. 7, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast.
Earnings webcast details: | |
Date: | Thursday, Aug. 7, 2025 |
Time: | 3:30 p.m. CDT / 4:30 p.m. EDT |
Location: | |
U.S. dial-in | +1 (800) 715-9871 |
International dial-in: | +1 (646) 307-1963 |
Conference ID: | 6342275 |
A replay of the webcast, the earnings press release, presentation slides, and supplemental financial disclosures will be available on the Investor Relations section of Solventum's website.
About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

| Last Trade: | US$80.68 |
| Daily Change: | 0.73 0.91 |
| Daily Volume: | 1,018,166 |
| Market Cap: | US$13.990B |
December 17, 2025 November 20, 2025 November 06, 2025 October 21, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load